Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf305 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Luca Mastorino und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Dermatologic Agents, Arthritis, Psoriatic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Numerous randomized controlled trials and real-life studies have shown risankizumab to be safe and effective for the treatment of psoriasis. However, real-life data on treatment for up to 4 years are lacking.
Objectives
We aimed to estimate the drug survival (DS), effectiveness and safety of risankizumab over a period of 208 weeks.
Methods
We included all consecutive patients between 1 January 2020 and 31 December 2024 with psoriasis or psoriatic arthritis who received at least one dose of risankizumab. Effectiveness was evaluated according to the achievement of 100% and 90% improvement in Psoriasis Area and Severity Index (PASI 100 and PASI 90, respectively). DS was evaluated using a Kaplan–Meier curve.
Results
In total, 545 patients were included in the study. Mean PASI decreased from 14 at baseline to 0.5 at 208 weeks. PASI 100 showed an increasing trend, achieved in 33% and 74% of patients at 16 and 208 weeks, respectively. A similar trend was seen for PASI 90, peaking at 208 weeks with 81% of patients achieving this outcome. The estimated DS at 208 weeks was 87.2% in patients at risk of treatment discontinuation. Biologic treatment-naïve patients showed a significantly more rapid response than biologic treatment-experienced patients. Having obesity and difficult-to-treat site involvement appeared to slow the response, with patients with difficult-to-treat site involvement having a lower risk of drug interruption compared with patients with no difficult-to-treat site involvement (hazard ratio 0.15, 95% confidence interval 0.07–0.31; P < 0.001). Safety was good, with just five patients interrupting their treatment due to an adverse event.
Conclusions
Our study indicates that risankizumab exhibited good effectiveness and favourable safety in a real-world setting for up to 4 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
ORCID-Profile: Eleonora Bongiovanni
Zitieren
APA
Mastorino, L., Dapavo, P., Ortoncelli, M., Stroppiana, E., Verrone, A., Astrua, C., Bongiovanni, E., Goso, F., Frassy, S., Pandullo, S., Quaglino, P., & Ribero, S. (2025). Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf305
Vancouver
Mastorino L, Dapavo P, Ortoncelli M, Stroppiana E, Verrone A, Astrua C, et al. Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf305
BibTeX
@article{Mastorino2025,
author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Stroppiana, Elena and Verrone, Anna and Astrua, Chiara and Bongiovanni, Eleonora and Goso, Federico and Frassy, Sophie and Pandullo, Sofia and Quaglino, Pietro and Ribero, Simone},
title = {Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf305}
}
EUVIMED